Why a Cancer Drug's Price Tag Has Almost Nothing to Do With What It Cost to Discover It
When a new cancer drug gets approved, the number that makes headlines is usually the price — not the science behind it. It's easy to assume the two are connected: bigger breakthrough, bigger price tag, bigger R&D bill to recoup. The data doesn't really back that up.
Between 2008 and 2022, the net launch price for a one-year course of a new cancer drug in the U.S. roughly doubled, from around $100,000 to $200,000. Across all tumor types, the median annual cost of a course of cancer treatment now sits at about $196,000 — and prices have been rising faster than inflation for years. Cell and gene therapies, the newest and most technically complex category, average $563,313 per course.
Here's the part that should give everyone pause: a 2025 analysis of cancer drug launch prices found that drugs priced higher didn't have more impressive clinical efficacy or stronger evidence behind them. Price and benefit weren't meaningfully connected. Separately, when the Institute for Clinical and Economic Review evaluated cancer drugs for cost-effectiveness in 2025, only one of three fell within a cost-effective range.
So if price doesn't track benefit, does it at least track what the drug cost to develop? That's murkier than you'd think. Older estimates put the average cost of bringing a new drug to market as high as $2.7 billion. But a more recent study, looking specifically at 10 cancer drugs, found a median development cost of $648 million — a fraction of the older figure. When the number used to justify pricing can swing by billions of dollars depending on which study you cite, "R&D costs" stops being a fixed fact and starts being a talking point.
None of this means cancer drug development isn't genuinely expensive, risky, and worth rewarding — it is. But it does mean the price tag on a treatment is a policy choice as much as an economic necessity, set by what the market will bear rather than a direct pass-through of discovery costs. That's the gap BioPolicy is interested in: not whether new cancer science is worth funding — it clearly is — but whether the price at the end of that pipeline reflects what it actually took to get there, or just what a system with very little pushback will allow.
Sources
- An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022 (PMC)
- Analysis: R&D Costs and Innovation Not Sole Drivers of Cancer Drug Prices — Managed Healthcare Executive
- Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds — AJMC
- High Cost of Cancer Medicines in the United States: Opportunities for Policy Reforms — JCO Oncology Practice